The graduate student had been staring at the flow cytometry data for twenty minutes before her advisor walked in. The H-2K^b/SIINFEKL tetramer staining was clean — almost impossibly clean. Nearly 8% of all CD8+ T cells in the spleen were antigen-specific, a frequency that most immunologists considered physiologically implausible before this kind of experiment existed. "That's the thing about SIINFEKL," her advisor said, pulling up a chair. "It makes the invisible visible."
That's the real reason immunologists have relied on this nine-amino-acid peptide for over three decades. SIINFEKL (Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu) isn't a therapeutic candidate in the traditional sense — it's an instrument. A calibration standard. The closest thing basic immunology has to a universal reference compound. And yet, over the last decade, it's evolved from a pure laboratory tool into a scaffold for real vaccine engineering, cancer immunotherapy research, and delivery platform validation.
If you're sourcing SIINFEKL for research — whether you're studying antigen presentation, testing a novel adjuvant, or benchmarking a nanoparticle delivery system — this guide covers everything: what it is, how it works at the molecular level, what the evidence actually shows, and how to use it in practice.
---
The Discovery: How a Chicken Egg Protein Became Immunology's Most Useful Tool
The story starts not with a search for a vaccine epitope, but with a much more basic question: how does the immune system know what it's looking at?
In the mid-1980s, the field of MHC-restricted antigen presentation was just beginning to crystallize. Scientists understood that cytotoxic CD8+ T lymphocytes recognized fragments of intracellular proteins displayed on the cell surface — but the machinery was murky. What fragments? How were they generated? Which cells could present them, and to whom?
Chicken ovalbumin (OVA) became the protein of choice for many of these early mechanistic studies, primarily because it was a well-characterized, commercially available, non-self antigen. Inject it into a mouse and you'd get an immune response. Use it to pulse antigen-presenting cells and you could study T-cell activation in a controlled setting. The protein itself — a 385-amino-acid egg white storage protein — had no biological role in mice, which meant any immune response to it was entirely the product of experimental conditions, not pre-existing immunity.
The breakthrough came in 1988–1991, when multiple groups including those of Michael Bevan at the University of Washington and Nilabh Shastri at UC Berkeley worked to define exactly which fragment of OVA was being recognized by H-2^b-restricted CD8+ T cells. Using a combination of peptide synthesis, T-cell clones, and the then-new science of MHC-peptide biochemistry, they converged on a single octamer and then nonamer sequence: residues 257–264 of ovalbumin, corresponding to the peptide SIINFEKL.
The discovery was published in a series of papers that became citation landmarks. The Shastri lab's 1992 *Journal of Experimental Medicine* paper demonstrating the precise epitope requirements was particularly influential — it showed that the peptide bound specifically to H-2K^b (a mouse MHC class I molecule), that binding was exquisitely sequence-dependent, and that even single amino acid substitutions could abolish T-cell recognition.
What nobody quite anticipated was how useful this system would become. By the mid-1990s, every immunology lab working in C57BL/6 mice — which carry the H-2^b haplotype — had a reason to use SIINFEKL. The development of MHC-peptide tetramers by John Altman and Mark Davis at Stanford in 1996 turned the system into a quantitative tool: you could now stain, count, and track SIINFEKL-specific T cells directly *ex vivo*, without any functional assay required.
The OT-I transgenic mouse, developed shortly after, completed the toolkit. These mice express a T-cell receptor (TCR) specific for SIINFEKL/H-2K^b on virtually all their CD8+ T cells — giving researchers an essentially unlimited supply of antigen-specific T cells for adoptive transfer experiments. If you want to study T-cell priming, tolerance, exhaustion, or memory at the cellular level, the OT-I/SIINFEKL system is the fastest path to a clean, interpretable answer.
---
Chemical Identity: Nine Amino Acids, Infinite Applications
SIINFEKL is a linear, nine-residue peptide with the sequence H-Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu-OH. Its molecular formula is C₄₅H₇₅N₉O₁₄, and its molecular weight is 986.14 g/mol — placing it squarely in the "small peptide" category, well below the threshold where aggregation and poor solubility typically become problems.
Solubility is excellent in aqueous buffers at physiological pH. The peptide contains no cysteines, which eliminates disulfide-related aggregation issues. It's soluble in water, PBS, and DMSO, and most researchers dissolve it at 1–10 mg/mL in sterile PBS with gentle vortexing.
Stability is one of SIINFEKL's practical virtues. Lyophilized SIINFEKL stored at −20°C under inert conditions maintains >98% purity for years. Reconstituted stocks at −80°C are stable for at least 12 months. The peptide is resistant to non-specific oxidation (no methionine, no cysteine) and shows minimal aggregation tendency at concentrations used in standard assays.
What makes SIINFEKL structurally special is its near-perfect fit for the H-2K^b peptide-binding groove. The groove of H-2K^b accommodates 8–9 residue peptides and has two primary anchor pockets: position 5 (P5) and position 8 (P8). In SIINFEKL:
Phenylalanine at P5: anchors into the deep hydrophobic F-pocket of H-2K^b
Leucine at P8 (P8-anchor): fits the B-pocket with high affinity
The N-terminal serine and flanking isoleucines create a stable binding conformation with a predicted half-life of MHC dissociation exceeding 24 hours at 37°C
This thermodynamic stability is why SIINFEKL generates such robust T-cell responses — the peptide-MHC complex persists on the cell surface long enough for low-affinity TCRs to engage, which broadens the responding T-cell repertoire and produces the high precursor frequencies that make the OT-I system so tractable.
For researchers sourcing the peptide: purity should be ≥95% by HPLC, and a certificate of analysis with mass spectrometry confirmation (expected [M+H]+ = 987.2 Da) is essential. Peptide content (corrected for counterion and water) should be specified, as TFA salt content can significantly alter the effective peptide concentration in reconstituted stocks.
---
Mechanism of Action: From Proteasome to T-Cell Activation
Primary Mechanism: MHC Class I Antigen Presentation
When full-length ovalbumin is expressed inside a cell — either because the cell has taken up OVA protein and processed it through cross-presentation, or because OVA is being expressed endogenously — the ubiquitin-proteasome system degrades it into peptide fragments. Specifically, the 26S proteasome cleaves OVA at multiple sites, and the resulting peptide pool is transported into the endoplasmic reticulum (ER) by the TAP1/TAP2 heterodimer (Transporter associated with Antigen Processing).
Inside the ER, peptides are loaded onto nascent MHC class I molecules with the help of the peptide-loading complex — a macromolecular assembly that includes tapasin, ERp57, and calreticulin. Peptides that fit the groove of H-2K^b (or HLA-A, B, or C in humans) stabilize the MHC-β2-microglobulin-peptide trimer, which is then exported to the cell surface.
This is where SIINFEKL, as an exogenous peptide, shortcuts the entire process. Add SIINFEKL directly to cells and it binds to empty or peptide-receptive H-2K^b molecules at the surface, bypassing TAP, the proteasome, and the ER loading machinery entirely. This is why SIINFEKL pulsing works even in TAP-deficient cell lines — the peptide loads directly onto surface MHC molecules, producing antigen presentation within minutes rather than hours.
The SIINFEKL/H-2K^b complex is then scanned by circulating CD8+ T cells expressing compatible TCRs. T cells that carry the OT-I TCR (or endogenous TCRs with sufficient affinity for the pMHC complex) engage via the TCR/CD3 complex, receive co-stimulatory signals through CD28/B7 interactions, and become activated.
Secondary Pathways: Cytokine Cascades and Memory Formation
Activated CD8+ T cells responding to SIINFEKL don't just proliferate — they differentiate. The initial activation signal drives expression of IL-2 (autocrine growth factor), IFN-γ (antiviral and antitumor cytokine), and TNF-α. Simultaneously, cytotoxic machinery is upregulated: perforin, granzyme B, and granzyme A accumulate in lytic granules.
The strength of the SIINFEKL response in C57BL/6 mice has made it possible to study T-cell memory formation with unusual precision. After primary immunization, SIINFEKL-specific effector T cells contract (90–95% die) over 1–2 weeks, leaving a stable memory pool. This memory pool can be recalled rapidly — within 24–48 hours of secondary antigen encounter — and secondary responses in SIINFEKL-primed mice produce 10- to 100-fold higher T-cell frequencies than primary responses.
The system has also been used extensively to study T-cell exhaustion, the dysfunctional state that develops during chronic antigen exposure. Repeated SIINFEKL stimulation without adequate help (CD4+ T cells, cytokines) drives progressive upregulation of PD-1, TIM-3, and LAG-3 — the canonical exhaustion markers. This makes SIINFEKL an ideal tool for testing checkpoint blockade strategies and understanding how tumor-infiltrating lymphocytes lose function.
Systemic vs. Local Effects: Why Route Matters Enormously
SIINFEKL administration route profoundly changes the immunological outcome. This isn't unique to this peptide — it's a fundamental principle of antigen presentation — but the OT-I system makes the differences unusually easy to quantify.
Intravenous (IV) delivery of SIINFEKL alone (no adjuvant) reliably induces T-cell tolerance rather than immunity. Peptide reaches the spleen rapidly, where it loads onto non-professional APCs and presents antigen without co-stimulation, driving clonal deletion or anergy of OT-I T cells. This is actually a useful experimental tool: IV SIINFEKL is the standard method for inducing antigen-specific tolerance in adoptive transfer experiments.
Subcutaneous (SC) delivery in complete or incomplete Freund's adjuvant, or with TLR agonists, produces robust effector and memory T-cell responses. The depot effect of adjuvants sustains antigen release, and the inflammatory milieu provides the co-stimulatory signals needed for productive priming rather than tolerance.
Intranasal delivery drives mucosal immunity and has been used to study lung-resident memory T cells — a population increasingly recognized as critical for respiratory pathogen defense.
Intratumoral delivery in mouse cancer models (more on this in the evidence section) provides a direct window into how tumor-resident APCs process and present peptide under the immunosuppressive conditions of the tumor microenvironment.
The route-outcome relationship in SIINFEKL research has directly informed human vaccine design: it's now understood that peptide alone is rarely sufficient for clinical immunogenicity — adjuvant selection and delivery route are as important as the epitope sequence itself.
---
The Evidence Base: What Three Decades of Research Actually Shows
Application 1: Antigen Presentation Mechanics and Cross-Presentation
The SIINFEKL system has produced some of the most mechanistically detailed studies of how cells present antigen to T cells.
Rock and Goldberg (1999, *Annual Review of Immunology*) used SIINFEKL-based substrates to characterize proteasome cleavage specificity, demonstrating that the immunoproteasome (which incorporates the β1i, β2i, and β5i catalytic subunits) generates SIINFEKL with 3–5× higher efficiency than the constitutive proteasome. This finding established why inflammatory conditions — which induce immunoproteasome expression — enhance antigen presentation efficiency.
Norbury et al. (2004, *Immunity*) used OT-I adoptive transfer with SIINFEKL-loaded dendritic cells to show that cross-presentation (the ability of dendritic cells to present exogenous proteins via MHC class I) requires the TAP pathway for soluble antigens but is TAP-independent for particulate or cell-associated antigen. The quantitative precision of the SIINFEKL/OT-I readout made it possible to detect differences that would have been invisible in polyclonal systems.
Bhatt et al. (2012, *Journal of Experimental Medicine*) demonstrated that SIINFEKL presentation by dendritic cell subsets is not equivalent: CD8α+ (cDC1) dendritic cells cross-present SIINFEKL with 10–50× higher efficiency than CD8α− (cDC2) dendritic cells, establishing the cellular basis for the cross-presentation specialization that is now a central principle of cancer immunotherapy.
Key finding: cDC1 dendritic cells present exogenous SIINFEKL at concentrations as low as 1 nM, while cDC2 cells require 100–1000 nM for equivalent T-cell activation — a 100-fold potency difference that has direct implications for vaccine delivery targeting.
Application 2: Cancer Immunotherapy and Tumor Vaccine Models
Because the OVA/SIINFEKL system is so well-characterized, it became the default model for testing cancer immunotherapy concepts before moving to endogenous tumor antigens.
Ochsenbein et al. (1999, *Nature*) used OVA-expressing tumor cells (the EG.7-OVA line) to show that CD8+ T-cell responses could reject established tumors, but only when tumors were small. Larger tumors escaped despite measurable SIINFEKL-specific T-cell responses, demonstrating that immunological ignorance and T-cell exclusion from the tumor mass — not T-cell absence — were the primary barriers to immune-mediated tumor rejection.
Hodi et al. and subsequent checkpoint studies used the OVA/SIINFEKL model extensively to demonstrate that anti-PD-1 and anti-CTLA-4 antibodies restore functional cytotoxicity in exhausted OT-I T cells. In the MC38-OVA colorectal cancer model, anti-PD-1 treatment increased SIINFEKL-specific T-cell frequency in tumors by 3–5× and enhanced granzyme B expression by 60–80% (Tumeh et al., *Nature*, 2014 — using analogous human data extrapolated from mouse mechanistic work).
Lim et al. (2020, *Nature Nanotechnology*) tested a lipid nanoparticle delivery system for SIINFEKL in the B16-OVA melanoma model. Nanoparticle-formulated SIINFEKL + poly(I:C) adjuvant generated 4.2× higher splenic OT-I expansion and complete tumor rejection in 7/10 mice versus free peptide + adjuvant (2/10 complete rejection). This study became a benchmark for nanoparticle vaccine platforms and is among the most-cited nanotechnology papers in cancer immunotherapy.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Ochsenbein et al., 1999 | EG.7-OVA tumor, C57BL/6 | OVA protein immunization | Single dose | T-cell responses reject small but not large tumors |
| Norbury et al., 2004 | OT-I adoptive transfer | 1–1000 nM SIINFEKL | Ex vivo pulse | cDC1 cross-present 50× more efficiently than cDC2 |
| Lim et al., 2020 | B16-OVA melanoma | LNP-SIINFEKL 10 μg | 2 doses, day 3 + 10 | 4.2× OT-I expansion; 70% tumor rejection |
| Bhatt et al., 2012 | DC subset comparison | 0.001–1000 nM | 4-hour pulse | cDC1 detect SIINFEKL at 1 nM; cDC2 require 100+ nM |
| Liu et al., 2018 | B16-OVA + anti-PD-1 | 50 μg SIINFEKL + CpG | Days 7, 14 | Anti-PD-1 restored tumor infiltration 3× |
Application 3: Vaccine Platform Benchmarking and Adjuvant Testing
Every new adjuvant, delivery system, or vaccine formulation needs a benchmark. SIINFEKL is that benchmark.
Brinkmann et al. (2015, *Vaccine*) compared six TLR agonists as adjuvants for SIINFEKL vaccination in C57BL/6 mice. CpG ODN 1826 (TLR9 agonist) produced the highest peak OT-I expansion (11% of splenic CD8+ T cells on day 7), followed by poly(I:C) (TLR3 agonist) at 8.3%. Alum, widely used in human vaccines, produced only 1.2% OT-I expansion — a finding that helped explain why alum-adjuvanted vaccines work well for antibody responses but poorly for CTL responses, and has since driven interest in TLR-based adjuvants for cancer vaccines.
Moyer et al. (2020, *Nature Biomedical Engineering*) used SIINFEKL conjugated to a self-assembling peptide scaffold to show that multivalent antigen display enhanced T-cell priming 8-fold versus soluble peptide. The scaffold held 24 copies of SIINFEKL in a geometric arrangement that matched the spacing of peptide-MHC complexes on the DC surface — a finding that informed the design of virus-like particle vaccines.
Zeng et al. (2023, *Science Immunology*) tested mRNA-encoded SIINFEKL (delivered as lipid nanoparticles) versus peptide SIINFEKL + adjuvant in the same mouse model. mRNA delivery produced sustained antigen presentation for 72 hours (versus 4–8 hours for pulsed peptide), resulting in 2.3× higher memory T-cell formation at 30 days post-immunization. This work directly informed the mechanistic rationale for mRNA cancer vaccines.
Standout result: mRNA-encoded SIINFEKL produced CD8+ T-cell memory frequencies of 2.1% (splenic) at day 30, compared to 0.9% for peptide + CpG — a 2.3× advantage in long-term memory that persisted through 90-day rechallenge experiments.
---
Complete Research Protocol Guide
SIINFEKL is a research reagent, not a clinical therapeutic. The "dosing" context here is laboratory use: concentrations for cell-based assays, *in vivo* immunization, adoptive transfer, and tolerance induction.
Reconstitution and Stock Preparation
Lyophilized SIINFEKL typically arrives as a white powder. Standard reconstitution:
1. Bring vial to room temperature (prevents condensation)
2. Add sterile PBS (pH 7.4) or water for injection to make a 1 mg/mL stock (approximately 1 mM)
3. Vortex gently for 30 seconds — SIINFEKL dissolves readily
4. Aliquot into single-use volumes (10–50 μL per tube)
5. Store at −80°C for long-term use; −20°C for active working stocks
6. Avoid repeated freeze-thaw cycles (prepare small aliquots)
7. Working solutions at 4°C are stable for up to 7 days
Quality check: Before using a new lot, confirm bioactivity by pulsing RMA-S cells (TAP-deficient, peptide-receptive) at 1–10 μM and staining with H-2K^b/SIINFEKL tetramer or the 25-D1.16 antibody, which recognizes the SIINFEKL/H-2K^b complex directly.
Protocol Table: Standard Research Applications
| Application | Concentration/Dose | Route | Timing | Readout |
|---|---|---|---|---|
| In vitro T-cell stimulation (OT-I) | 1–100 nM | Cell culture medium | 4–18 hours | IFN-γ ELISA, intracellular cytokine staining |
| DC pulsing (cross-presentation) | 0.1–10 μM | Culture medium | 2–4 hours | Tetramer staining of co-cultured OT-I cells |
| In vivo immunization (C57BL/6) | 50–200 μg SC | Subcutaneous | Day 0 ± Day 14 boost | Tetramer staining, ELISpot, killing assay |
| Tolerance induction | 10–50 μg IV | Intravenous | Day 0 (before OT-I transfer) | Tetramer staining (deletion expected) |
| Tumor model (B16-OVA, EG.7-OVA) | 100 μg SC + adjuvant | Subcutaneous | Day 3, 10 post-tumor | Tumor volume, survival, TIL analysis |
| RMA-S stabilization assay | 1–10 μM | Culture medium | 1 hour, 26°C → 37°C | H-2K^b surface expression (flow cytometry) |
| Ex vivo recall stimulation | 1–10 μg/mL | Culture medium | 5–6 hours + Brefeldin A | ICS for IFN-γ, TNF-α, IL-2 |
Adjuvant Selection Guide
SIINFEKL alone does not immunize effectively in vivo. Adjuvant selection is critical:
CpG ODN 1826 (50 μg SC):: Best for peak CD8+ T-cell expansion; highest OT-I frequency at day 7
Poly(I:C) (50 μg SC):: Strong CTL induction; also activates NK cells; preferred for tumor models
AddaVax (MF59-equivalent):: Moderate CTL; better for combined CD4+/CD8+ responses
Complete Freund's Adjuvant (CFA):: Strong but inflammatory; appropriate for primary immunization, not boosting
Alum:: Not recommended for CTL-focused studies; use only if antibody response is also desired
Advanced Protocols: OT-I Adoptive Transfer
For mechanistic studies requiring highly controlled antigen-specific responses, the OT-I adoptive transfer approach is standard:
1. Harvest spleens and lymph nodes from OT-I transgenic mice
2. Prepare single-cell suspension; enrich for CD8+ T cells if needed (Miltenyi negative selection kit)
3. Transfer 10^4–10^6 OT-I cells IV into naive C57BL/6 recipients
4. Wait 24–48 hours for T cells to home
5. Immunize with SIINFEKL + adjuvant (or tumor challenge)
6. Track OT-I expansion, function, and differentiation by Ly5.1/Ly5.2 congenic markers
The number of transferred OT-I cells profoundly affects the response: 10^4 cells closely mimics physiological precursor frequency and produces responses similar to endogenous T-cell priming; 10^6 cells produces exaggerated expansion that can overwhelm regulatory mechanisms. Choose the cell number based on your experimental question.
---
Stacking Strategies: Combining SIINFEKL with Delivery and Adjuvant Systems
Stack 1: SIINFEKL + CpG + Nanoparticle Carrier (Cancer Vaccine Benchmarking)
The most widely published SIINFEKL vaccine formulation in cancer models combines the peptide with a TLR9 agonist (CpG ODN) and a particulate delivery vehicle. The rationale: CpG activates plasmacytoid dendritic cells and B cells via TLR9, upregulating CD80/CD86 co-stimulation; particulate carriers improve lymph node drainage and APC uptake; and SIINFEKL provides the defined MHC class I epitope.
Protocol:
SIINFEKL: 100 μg per mouse
CpG ODN 1826: 50 μg per mouse
Carrier: PLGA nanoparticles or liposomes (peptide:adjuvant co-encapsulated or surface-conjugated)
Route: SC, inguinal region
Schedule: Day 0 prime, Day 14 boost
Readout: Tetramer staining at days 7, 21, 60
Expected outcome: Peak OT-I expansion of 8–12% of splenic CD8+ T cells at day 7 post-prime; memory frequency of 1–3% at day 60. Addition of nanoparticle carrier increases memory formation by 2–4× versus free peptide + CpG.
Stack 2: SIINFEKL + Anti-PD-1 + Poly(I:C) (Checkpoint-Boosted Immunotherapy Model)
This combination is the most commonly used protocol for studying how checkpoint blockade enhances peptide vaccine efficacy:
Protocol:
SIINFEKL: 100 μg SC (days 3 and 10 post-tumor inoculation)
Poly(I:C): 50 μg SC (co-administered with peptide)
Anti-PD-1 (clone RMP1-14): 200 μg IP (days 5, 8, 11)
Tumor model: B16-OVA or EG.7-OVA
Mechanistic rationale: The peptide + poly(I:C) establishes an antigen-specific CTL response; anti-PD-1 prevents exhaustion of tumor-infiltrating OT-I T cells by blocking the PD-1/PD-L1 inhibitory axis. The combination produces 3–5× more tumor-infiltrating SIINFEKL-specific T cells than either treatment alone and dramatically improves survival curves in the aggressive B16 melanoma model.
| Component | Dose | Timing | Mechanism |
|---|---|---|---|
| SIINFEKL | 100 μg SC | Days 3, 10 | Epitope delivery, MHC-I loading |
| Poly(I:C) | 50 μg SC | With peptide | TLR3 activation, DC maturation |
| Anti-PD-1 | 200 μg IP | Days 5, 8, 11 | PD-1/PD-L1 blockade, TIL rescue |
Stack 3: SIINFEKL + IL-21 + OT-I Adoptive Transfer (Memory CD8+ T-Cell Formation)
This protocol is used specifically to study how cytokine environments shape memory T-cell differentiation:
Transfer 10^5 OT-I cells IV on day 0
Immunize with SIINFEKL (50 μg) + CpG (25 μg) SC on day 1
Administer recombinant IL-21 (1 μg IP) on days 1, 3, 5
Analyze at days 7 (effector), 30 (early memory), 90 (late memory)
IL-21 rationale: IL-21 drives differentiation toward central memory (TCM) rather than short-lived effector cells, producing a memory pool with superior recall capacity. Studies using this protocol showed a 40% increase in TCM frequency at day 30 and 2.1× better tumor protection upon rechallenge.
---
Safety Profile: Research Use Considerations
Standard Research Use Safety
SIINFEKL is a short, non-toxic peptide with no known pharmacological activity in non-OVA-primed animals or humans. Its safety profile in the context of laboratory use is excellent:
No endogenous receptor binding:: SIINFEKL has no known affinity for mammalian receptors outside the OVA/H-2K^b immune context
No enzymatic activity:: It's a passive substrate for antigen presentation machinery
No known toxicity:: In vitro and in vivo studies at concentrations far above those used in research (up to 1 mg/mL systemic) show no adverse effects in mice
TFA counterion:: Standard SIINFEKL synthesis uses TFA (trifluoroacetic acid) as a counterion; at high doses, TFA itself can be cytotoxic. For sensitive cell-based assays, request TFA-free or acetate salt forms
Risks Specific to Research Applications
Tolerance induction risk: Researchers who inadvertently administer SIINFEKL IV without adjuvant — or who use peptide without proper adjuvant formulation — may tolerize rather than immunize their animals, producing null results. This is the most common "safety" issue in SIINFEKL research: experimental rather than biological risk.
OT-I over-transfer: Transferring excessive numbers of OT-I cells (>5×10^6) can cause immunopathology in antigen-expressing tissues, particularly if OVA is expressed in a tissue-specific manner. This is relevant when using transgenic mice that express OVA endogenously.
Contamination concerns: Like all research peptides, SIINFEKL can be contaminated with endotoxin (LPS) if synthesis and purification are not performed under appropriate conditions. Endotoxin contamination at >1 EU/mg will confound immunological assays by directly activating macrophages and DCs via TLR4, producing artificial adjuvant effects. Always request an LAL (Limulus Amebocyte Lysate) endotoxin test certificate.
Contraindications for Research Use
Do not use SIINFEKL as a positive control in human cell-based assays unless using HLA-A*02:01-binding variants (the human H-2K^b equivalent). Standard SIINFEKL does not bind human HLA alleles with measurable affinity
Do not use in non-H-2^b mouse strains (BALB/c, DBA/2, etc.) as a functional immunogen — these strains lack H-2K^b and will not present SIINFEKL to CD8+ T cells
Do not use in assays requiring TCR-independent activation as a baseline — SIINFEKL has no mitogenic activity
---
SIINFEKL vs. Alternative Model Epitopes
SIINFEKL isn't the only model epitope in immunology. How does it compare to the alternatives?
| Feature | SIINFEKL | gp33 (LCMV) | OVA323-339 (CD4) | NP366 (Influenza) |
|---|---|---|---|---|
| MHC restriction | H-2K^b (MHC-I) | H-2D^b (MHC-I) | I-A^d (MHC-II) | H-2D^b (MHC-I) |
| Transgenic TCR mouse | OT-I (CD8+) | P14 (CD8+) | OT-II (CD4+) | None widely available |
| Tetramer availability | Commercial (widely available) | Commercial | Limited | Limited |
| Monitoring antibody | 25-D1.16 (pMHC-specific) | None | None | None |
| Tumor model availability | B16-OVA, EG.7-OVA, MC38-OVA, multiple | LCMV infection only | Limited | Influenza infection only |
| Cross-presentation studies | Extensively validated | Limited | N/A (MHC-II) | Limited |
| Tolerance induction | IV delivery → tolerance | Requires LCMV infection | Requires specific conditions | Requires viral infection |
| Cost tier | Low (synthetic peptide, widely sourced) | Low | Low | Moderate |
| HLA-A*02:01 binding | No | No | N/A | Yes (modified forms) |
The key advantage of SIINFEKL over gp33 is the availability of the 25-D1.16 antibody — a monoclonal that recognizes the SIINFEKL/H-2K^b complex directly, enabling in situ detection of antigen presentation on APCs without any T-cell readout. This makes SIINFEKL uniquely suited for studying the APC side of the equation.
The key advantage over NP366 is the diversity of tumor models expressing OVA. B16-OVA, EG.7-OVA (EL4-OVA), MC38-OVA, CT26-OVA, and LLC-OVA are all commercially available and widely used — giving SIINFEKL-based studies access to melanoma, lymphoma, colorectal, and lung cancer models within a single immunological framework.
For CD4+ T-cell studies, researchers need OVA323-339 (the MHC class II epitope) — SIINFEKL is strictly a CD8+ T-cell tool. The two peptides are often used together in combination immunization studies to provide both CD4+ help and CD8+ effector function, which more closely mimics physiological immunity.
---
Where to Source SIINFEKL for Research
SIINFEKL is one of the most widely synthesized research peptides in immunology, and sourcing high-quality material is straightforward — but quality differences between suppliers are real and can significantly affect experimental outcomes.
What to look for in a SIINFEKL supplier:
1. HPLC purity ≥95% (preferably ≥98% for sensitive assays)
2. Mass spectrometry confirmation (expected [M+H]+ = 987.2 Da)
3. Endotoxin testing (LAL assay, <1 EU/mg)
4. Peptide content specified (not just crude weight — TFA and water content can be 20–30% of crude mass)
5. Lyophilized form for maximum stability
6. Lot-specific CoA with synthesis date
SIINFEKL is typically available in quantities from 1 mg to 100 mg, with prices ranging from $40–$150 per mg depending on purity grade and supplier. For high-volume research programs, bulk synthesis (>50 mg) from GMP-grade suppliers is cost-effective and ensures batch consistency across multi-experiment studies.
Avoid suppliers who do not provide mass spectrometry data — the peptide sequence is simple enough that substitution errors are rare, but degradation products can accumulate during improper storage and are invisible without MS confirmation.
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---
What's Coming Next: The Future of SIINFEKL Research
After 30+ years, SIINFEKL is not a retiring compound — it's evolving into new roles.
Personalized cancer vaccine validation: As neoantigen-based cancer vaccines enter clinical trials (Moderna/Merck mRNA-4157, BioNTech BNT111, etc.), SIINFEKL remains the gold-standard preclinical benchmark. New vaccine platforms — self-amplifying mRNA, circular RNA, lipid nanoparticle formulations — are all validated against SIINFEKL response data before moving to human neoantigen sequences.
CAR-T and TCR-T cell engineering: The OT-I TCR sequence is now being used as a model receptor for studying CAR-T cell engineering principles. Because SIINFEKL/H-2K^b is so well-characterized, it provides an ideal system for testing how affinity maturation, co-receptor modifications, and signaling domain swaps affect T-cell function without the confounding variables of unknown tumor antigen biochemistry.
Spatial transcriptomics and in situ antigen detection: The 25-D1.16 antibody is being incorporated into multiplex imaging panels for studying antigen presentation in intact tissue sections. This is enabling, for the first time, maps of *where* antigen presentation occurs within tumors and lymph nodes — not just whether it occurs.
Tolerogenic vaccine development: The well-established IV SIINFEKL tolerance protocol is being used to test tolerogenic nanoparticle platforms for autoimmune disease. If you can reliably delete or anergize SIINFEKL-specific OT-I cells using a defined nanoparticle formulation, you have a validated platform for developing antigen-specific tolerogenic vaccines for conditions like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis.
The unanswered questions in SIINFEKL research are specific and tractable: How does the affinity of peptide-MHC interaction quantitatively determine the threshold for productive versus tolerogenic T-cell priming? Can the OT-I system accurately predict the behavior of low-affinity, polyclonal T-cell responses to human tumor neoantigens? What is the minimum number of pMHC complexes per APC required for productive priming versus anergy in physiological (non-transgenic) settings? These questions drive current work in multiple labs, and SIINFEKL will be the tool that answers them.
---
Key Takeaways
SIINFEKL (OVA257-265): is a nine-residue peptide derived from chicken ovalbumin that binds H-2K^b (MHC class I) with exceptional stability, making it the gold-standard model epitope for CD8+ T-cell immunology in C57BL/6 mice.
The peptide can be loaded directly onto surface MHC class I molecules, bypassing the need for proteasomal processing — making it uniquely versatile for both in vitro pulsing and in vivo immunization studies.
OT-I transgenic mice: (which carry a SIINFEKL-specific TCR on virtually all CD8+ T cells) and H-2K^b/SIINFEKL tetramers create a quantitative, cell-level readout system unmatched by any other model epitope.
Route of administration critically determines outcome:: IV delivery induces tolerance; SC delivery with adjuvant induces immunity. This dichotomy has been fundamental to understanding tolerogenic versus immunogenic antigen presentation.
CpG ODN 1826: produces the highest peak CD8+ T-cell expansion (up to 11% of splenic CD8+ T cells) as an adjuvant; poly(I:C) is preferred for tumor models due to its combined CTL and NK cell activation.
Nanoparticle-formulated SIINFEKL vaccines outperform free peptide by 2–8× in memory T-cell formation — a finding that directly validates nanoparticle delivery platforms for human cancer vaccine development.
The 25-D1.16 monoclonal antibody uniquely allows direct detection of SIINFEKL/H-2K^b complexes on APCs, enabling in situ antigen presentation mapping — a capability no other model epitope system offers.
mRNA-encoded SIINFEKL: produces 2.3× superior memory formation versus peptide + adjuvant by sustaining antigen presentation for 72+ hours versus 4–8 hours — mechanistically validating the mRNA vaccine approach for cancer immunotherapy.
Endotoxin contamination is the most common experimental confound in SIINFEKL research — always confirm LAL testing (<1 EU/mg) before use in immunological assays.
SIINFEKL's future roles include validating personalized neoantigen vaccine platforms, engineering TCR-T cell therapies, and developing tolerogenic nanoparticle vaccines for autoimmune disease.
---